Sarah Scagliarini

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Matteo Santoni, Sebastiano Buti, Zin Myint et al. · European Urology Oncology · 2023 · 52 citations · Full text

Differential Effectiveness, Urology, Genitourinary Cancer +7

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Giuseppe Procopio, Mélanie Claps, Chiara Pircher et al. · Tumori Journal · 2022 · 46 citations · Full text

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Matteo Santoni, Francesco Massari, Zin Myint et al. · Targeted Oncology · 2023 · 34 citations · Full text

Immuno-oncology Combinations, Urology, Kidney Transplant +7

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

Matteo Santoni, Daniel Y.C. Heng, Sergio Bracarda et al. · Cancers · 2019 · 31 citations · Full text

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study

Carlo Buonerba, Giuseppe Di Lorenzo, Gregory R. Pond et al. · Frontiers in Pharmacology · 2016 · 28 citations · Full text